Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 48

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 48
---
 Years range 
     5-5.37 years 

    Dividend yield 
     - 

Unrecognized
compensation expenses as of September 30, 2025 was $0.13 million to be recognized through September 2026. The Company recognized approximately
$5.3 million in stock-based compensation in the nine months ended September 30, 2025.

    12

Note
6. Segment Information

The
Company operates in one reportable segment related to the development and commercialization of pharmaceuticals targeting neurologic and
neuropsychiatric disorders. The CODM for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO
reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial
performance and allocating resources. Accordingly, the Company has determined that it has a single reportable and operating segment structure.
The CEO uses aggregate net loss to allocate resources in the annual budgeting and forecasting process and also uses that measure as a
basis for evaluating financial performance regularly by comparing actual results with established budgets and forecasts.

The
accounting policies of the Company’s single segment are the same as those described in the summary of significant accounting policies
within Note 1. The CEO assesses performance for the Company and decides how to allocate resources based on the aggregate net loss that
is also reported on the statement of operations as net loss. The measure of segment assets is reported on the balance sheets as total
assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 Schedule
of segment information

    Three Months Ended
                                                                                Septembder 30,  
    Nine Months Ended
                                                                                September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Revenues 
    $-  
    $-  
    $-  
    $- 
  
    Less segment expenses: 

    Operating costs: 

    General and administrative expenses 
     386,951  
     5,378,744  
     7,264,808  
     6,999,981 
  
    Related party travel costs 
     -  
     -  
     -  
     370,500 
  
    Research and development expenses 
     759,525  
     627,434